Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

  • In development
  • GID-TA11690
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Inclacumab within its marketing authorisation for treating sickle cell disease ID6551